Literature DB >> 23632265

Retrospective and prospective data collection compared in the Dutch End Of Life in Dementia (DEOLD) study.

Jenny T van der Steen1, Miel W Ribbe, Luc Deliens, Giselka Gutschow, Bregje D Onwuteaka-Philipsen.   

Abstract

Studying end of life in dementia patients is challenging because of ill-defined prognoses and frequent inability to self-report. We aim to quantify and compare (1) feasibility and (2) sampling issues between prospective and retrospective data collection specific to end-of-life research in long-term care settings. The observational Dutch End of Life in Dementia study (DEOLD; 2007 to 2011) used both prospective data collection (28 facilities; 17 nursing home organizations/physician teams; questionnaires between January 2007 and July 2010, survival until July 2011) and retrospective data collection (exclusively after death; 6 facilities; 2 teams, questionnaires between November 2007 and March 2010). Prospective collection extended from the time of admission to the time after death or conclusion of the study. Prospectively, we recruited 372 families: 218 residents died (59%) and 184 (49%) had complete physician and family after-death assessments. Retrospectively, 119 decedents were enrolled, with 64 (54%) complete assessments. Cumulative data collection over all homes lasted 80 and 8 years, respectively. Per complete after-death assessments in a year, the prospective data collection involved 37.9 beds, whereas this was 7.9 for the retrospective data collection. Although age at death, sex, and survival curves were similar, prospectively, decedents' length of stay was shorter (10.3 vs. 31.4 mo), and fewer residents had advanced dementia (39% vs. 54%). Regarding feasibility, we conclude that prospective data collection is many fold more intensive and complex per complete after-death assessment. Regarding sampling, if not all are followed until death, it results in right censoring and in different, nonrepresentative samples of decedents compared with retrospective data collection. Future work may adjust or stratify for dementia severity and length of stay as key issues to promote comparability between studies.

Entities:  

Mesh:

Year:  2014        PMID: 23632265     DOI: 10.1097/WAD.0b013e318293b380

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  19 in total

Review 1.  [Provision of palliative care for people with advanced dementia].

Authors:  J Diehl-Schmid; L Riedl; U Rüsing; J Hartmann; M Bertok; C Levin; J Hamann; M Arcand; S Lorenzl; B Feddersen; R J Jox
Journal:  Nervenarzt       Date:  2018-05       Impact factor: 1.214

2.  Evaluation of a Palliative Care Program for Nursing Homes in 7 Countries: The PACE Cluster-Randomized Clinical Trial.

Authors:  Lieve Van den Block; Elisabeth Honinx; Lara Pivodic; Rose Miranda; Bregje D Onwuteaka-Philipsen; Hein van Hout; H Roeline W Pasman; Mariska Oosterveld-Vlug; Maud Ten Koppel; Ruth Piers; Nele Van Den Noortgate; Yvonne Engels; Myrra Vernooij-Dassen; Jo Hockley; Katherine Froggatt; Sheila Payne; Katarzyna Szczerbinska; Marika Kylänen; Giovanni Gambassi; Sophie Pautex; Catherine Bassal; Stefanie De Buysser; Luc Deliens; Tinne Smets
Journal:  JAMA Intern Med       Date:  2020-02-01       Impact factor: 21.873

3.  Factors related to establishing a comfort care goal in nursing home patients with dementia: a cohort study among family and professional caregivers.

Authors:  Mirjam C van Soest-Poortvliet; Jenny T van der Steen; Henrica C W de Vet; Cees M P M Hertogh; Bregje D Onwuteaka-Philipsen; Luc H J Deliens
Journal:  J Palliat Med       Date:  2014-12       Impact factor: 2.947

4.  Protocol for an observational cohort study identifying factors predicting accurately end of life in dementia with Lewy bodies and promoting quality end-of-life experiences: the PACE-DLB study.

Authors:  Melissa J Armstrong; Henry L Paulson; Susan M Maixner; Julie A Fields; Angela M Lunde; Bradley F Boeve; Carol Manning; James E Galvin; Angela S Taylor; Zhigang Li
Journal:  BMJ Open       Date:  2021-05-26       Impact factor: 2.692

5.  Incidence of pneumonia in nursing home residents with dementia in the Netherlands: an estimation based on three differently designed studies.

Authors:  T P Zomer; T VAN DER Maaden; A B VAN Gageldonk-Lafeber; S C DE Greeff; J T VAN DER Steen; L Verhoef
Journal:  Epidemiol Infect       Date:  2017-07-03       Impact factor: 4.434

6.  Predictors of spiritual care provision for patients with dementia at the end of life as perceived by physicians: a prospective study.

Authors:  Jenny T van der Steen; Marie-José He Gijsberts; Cees Mpm Hertogh; Luc Deliens
Journal:  BMC Palliat Care       Date:  2014-12-19       Impact factor: 3.234

7.  Caregivers' understanding of dementia predicts patients' comfort at death: a prospective observational study.

Authors:  Jenny T van der Steen; Bregje D Onwuteaka-Philipsen; Dirk L Knol; Miel W Ribbe; Luc Deliens
Journal:  BMC Med       Date:  2013-04-11       Impact factor: 8.775

8.  Feedback on end-of-life care in dementia: the study protocol of the FOLlow-up project.

Authors:  Jannie A Boogaard; Mirjam C van Soest-Poortvliet; Johannes R Anema; Wilco P Achterberg; Cees M P M Hertogh; Henrica C W de Vet; Jenny T van der Steen
Journal:  BMC Palliat Care       Date:  2013-08-07       Impact factor: 3.234

9.  Effectiveness of post-exposition prophylaxis with oseltamivir in nursing homes: a randomised controlled trial over four seasons.

Authors:  Marianne Ab van der Sande; Adam Meijer; Fatmagül Sen-Kerpiclik; Remko Enserink; Herman Jm Cools; Piet Overduin; José M Ferreira; Marie-José Veldman-Ariessen
Journal:  Emerg Themes Epidemiol       Date:  2014-09-10

10.  Predicting mortality in patients treated differently: updating and external validation of a prediction model for nursing home residents with dementia and lower respiratory infections.

Authors:  Simone P Rauh; Martijn W Heymans; David R Mehr; Robin L Kruse; Patricia Lane; Neil W Kowall; Ladislav Volicer; Jenny T van der Steen
Journal:  BMJ Open       Date:  2016-08-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.